Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study

Table 4 Univariable and multivariable analysis for overall survival (OS)

Variables	Univariable analysis		Multivariable analysis
Variables	HR (95% CI)	P value	HR (95% CI)	P value
Treatment regimen
mFOLFIRINOX vs Gemox	0.595 (0.312–1.135)	0.099	0.547 (0.264–1.131)	0.103
Age
>58 vs ≤58	1.089 (0.567–2.092)	0.798
Sex
male vs female	0.896 (0.650–1.235)	0.504
ECOG
1 vs 0	1.709 (0.883–3.310)	0.112	2.148 (1.028–4.488)	0.042
Primary tumor sites
Intrahepatic	Ref
Hilar	1.609 (0.827–3.129)	0.161	2.123 (1.023–4.402)	0.043
Distal	0.893 (0.207–3.846)	0.879	0.890 (0.199–3.983)	0.878
Disease status
Metastasis vs Locally advanced	0.939 (0.660–1.335)	0.724
Liver metastasis	1.393 (0.716–2.710)	0.329
CA19–9
>40 vs ≤40	3.198 (1.237–8.266)	0.016	4.972 (1.768–13.980)	0.002

Bold values are statistically significant (p ≤ 0.05)
Ref reference, HR hazard ratio, CI confidence interval, ECOG Eastern Cooperative Oncology Group

ISSN: 1471-2407